Skip to main content

Maetzold Derek J's Form 4 filing

Castle Biosciences Inc (CSTL) · filed Jan 15, 2025

Accession no.
0001447362-25-000014
Filed
Jan 15, 2025
Trade date
Jan 13, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 21 non-derivative transactions. Open-market sales total $71.9K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Maetzold Derek JCIK 0001239501Director, Officer (Pres. & Chief Exec. Officer)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jan 13, 2025Common StockSSaleDisposed−556$27.51F2−$15,295.5681,248Direct
Jan 13, 2025Common StockSSaleDisposed−285$27.51F2−$7,840.3571,301Indirect
Jan 13, 2025Common StockSSaleDisposed−267$27.51F2−$7,345.1760,780Indirect
Jan 13, 2025Common StockSSaleDisposed−85$27.51F2−$2,338.355,175Indirect
Jan 13, 2025Common StockSSaleDisposed−85$27.51F2−$2,338.355,169Indirect
Jan 13, 2025Common StockSSaleDisposed−85$27.51F2−$2,338.355,169Indirect
Jan 13, 2025Common StockSSaleDisposed−85$27.51F2−$2,338.355,169Indirect
Jan 13, 2025Common StockSSaleDisposed−399$28.65F9−$11,431.3580,849Direct
Jan 13, 2025Common StockSSaleDisposed−204$28.65F9−$5,844.671,097Indirect
Jan 13, 2025Common StockSSaleDisposed−192$28.65F9−$5,500.860,588Indirect
Jan 13, 2025Common StockSSaleDisposed−60$28.65F9−$1,7195,115Indirect
Jan 13, 2025Common StockSSaleDisposed−61$28.65F9−$1,747.655,108Indirect
Jan 13, 2025Common StockSSaleDisposed−60$28.65F9−$1,7195,109Indirect
Jan 13, 2025Common StockSSaleDisposed−61$28.65F9−$1,747.655,108Indirect
Jan 13, 2025Common StockSSaleDisposed−31$29.48F10−$913.8880,818Direct
Jan 13, 2025Common StockSSaleDisposed−16$29.48F10−$471.6871,081Indirect
Jan 13, 2025Common StockSSaleDisposed−15$29.48F10−$442.260,573Indirect
Jan 13, 2025Common StockSSaleDisposed−5$29.48F10−$147.45,110Indirect
Jan 13, 2025Common StockSSaleDisposed−4$29.48F10−$117.925,104Indirect
Jan 13, 2025Common StockSSaleDisposed−5$29.48F10−$147.45,104Indirect
Jan 13, 2025Common StockSSaleDisposed−4$29.48F10−$117.925,104Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

This transaction was executed in multiple trades at prices ranging from $27.15 to $28.00, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

F9

This transaction was executed in multiple trades at prices ranging from $28.17 to $29.05, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

F10

This transaction was executed in multiple trades at the price of $29.48, inclusive. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

Referenced by the price of 7 transactions in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)